Professor/Associate Professor in Medicine Obesity and Metabolism job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY – NTNU | 223116 – Times…

Posted on by

About the position

At the Faculty of Medicine and Health Sciences, we have a vacancy for a 100% permanent position as Professor/Associate Professor in Medicine (Obesity and Metabolism).

The position is at theDepartment of Clinical and Molecular Medicine.

You willreportto the head of department.

Duties of the position

The appointee is expected to teach within their relevant expertise across all study programmes at the Faculty.

The person appointed must comply with the decisions about changes due to developments in the subject area, and the organizational changes that may result from decisions regarding the university's activities.

Required selection criteria

The position of Professorwithin obesity and metabolism requires that you meet the criteria in theRegulations concerning appointment and promotion to teaching and research posts section 1-2.

In addition to formal qualifications in teaching at university level, you must document

For appointment as a professor, an academic level conforming to establishednational standardsis required

The position of Associate Professor within obesity and metabolism requires that you meet the criteria in theRegulations concerning appointment and promotion to teaching and research posts section 1-4.

You will be expected to deliver high-quality teaching at undergraduate and postgraduate levels, and undertake supervision of Masters and Doctoral candidates. Evaluation of these skills will be based on documented experience and relevant teaching qualifications. Applicants with teaching experience at university level are preferred. Quality and breadth of the teaching qualifications will be evaluated.

NTNU is committed to following evaluation criteria for research quality according toThe San Francisco Declaration on Research Assessment - DORA.This means that we pay special attention to the quality and professional breadth of these works. We also consider experience from research management and participation in research projects.

You must document relevant basic competence forteaching and supervision at university/higher education-level. If this cannot be documented, you are required to complete an approved course in university teaching within two years of commencement. NTNU offers qualifying courses.

It is a prerequisite that within three years of appointment, new employees who do not speak a Scandinavian language can demonstrate skills in Norwegian or another Scandinavian language equivalent to level three in thecourse for Norwegian for speakers of other languages at the Department of Language and Literature at NTNU.

Please see theRegulations concerning appointment and promotion to teaching and research posts for general criteria for the position.

Preferred selection criteria

Personal characteristics

In the assessment of the best qualified applicant, we will emphasize education, experience and personal suitability as well as your motivation for the position.

We offer

Salary and conditions

In a position as professor (code 1013) you will normally be remunerated from gross NOK 704 900,- to NOK 900 000,- per year,depending on qualifications and seniority. From the salary, 2% is deducted as a contribution to the Norwegian Public Service Pension Fund.

In a position as associate professor (code 1011) you will normally be remunerated from gross NOK 573 100,- to NOK 704 900,- per year,depending on qualifications and seniority. From the salary, 2% is deducted as a contribution to the Norwegian Public Service Pension Fund.

The engagement is to be made in accordance with the regulations in force concerning State Employees and Civil Servants, and the acts relating to Control of the Export of Strategic Goods, Services and Technology. Candidates who by assessment of the application and attachment are seen to conflict with the criteria in the latter law will be prohibited from recruitment to NTNU. After the appointment you must assume that there may be changes in the area of work.

It is a prerequisite that you can be present at and accessible to the institution on a daily basis.

About the application

The application and supporting documentation must be in English.

Please note that applications are only evaluated based on the information available on the application deadline. You should ensure that your application shows clearly how your skills and experience meet the criteria which are set out above.

If, for any reason, you have taken a career break or have had an atypical career and wish to disclose this in your application, the selection committee will take this into account, recognizing that the quantity of your research may be reduced as a result.

The application must include:

Joint works will be considered. If it is difficult to identify your contribution to joint works, you must attach a brief description of your participation.

Your application will be considered by an expert committee and the most suitable applicants will be invited to interview and to deliver a lecture.

General information

A good working environment is characterized by diversity. We encourage qualified candidates to apply, regardless of their gender, functional capacity or cultural background. NTNU wishes to increase the proportion of women in its academic positions, and women are therefore encouraged to apply.

As an employee at NTNU, you must at all times adhere to the changes that the development in the subject entails and the organizational changes that are adopted.

Under the Freedom of Information Act (offentleglova), your name, age, position and municipality may be made public even if you have requested not to have your name entered on the list of applicants.

If you have any questions about the position, please contact head of department Torstein Baade R, telephone +47 99 61 40 25, emailtorstein.ro@ntnu.no. If you have any questions about the recruitment process, please contact Yngve Lorentzen, e-mail:yngve.lorentzen@ntnu.no

Please submit your application and supporting documentation via jobbnorge.no.

Application deadline: 15.09.2020

The city of Trondheimis a modern European city with a rich cultural scene. Trondheim is the innovation capital of Norway with a population of 200,000. The Norwegian welfare state, including healthcare, schools, kindergartens and overall equality, is probably the best of its kind in the world. Professional subsidized day-care for children is easily available. Furthermore, Trondheim offers great opportunities for education (including international schools) and possibilities to enjoy nature, culture and family life and has low crime rates and clean air quality.

NTNU - knowledge for a better world

The Norwegian University of Science and Technology (NTNU) creates knowledge for a better world and solutions that can change everyday life.

The Faculty of Medicine and Health Sciences (MH) is one of NTNUs largest faculties with about 1800 employees (

1300 full-time equivalents). The Facultys main activities are education and research in close integration with St Olavs Hospital. For further information, see:https://www.ntnu.edu/mh.

Deadline15th September2020EmployerNTNU - Norwegian University of Science and TechnologyMunicipalityTrondheimScopeFulltimeDurationPermanentJobbnorge ID186952

More here:

Professor/Associate Professor in Medicine Obesity and Metabolism job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 223116 - Times...

Medical Bioinformatics Market shares and strategies of key players – BioSpace

Posted on by

Bioinformatics involves the development and application of novel informatics techniques in the field of biology. It improves the methods of storing, organizing, retrieving and analyzing biological data. Major activity in bioinformatics is to develop software tools in order to generate useful biological knowledge database. In molecular biology, bioinformatics techniques such as signal processing allow extraction of useful results from large amount of raw data. In the field of genetics it helps in sequencing, annotating genomes and to observe mutations. Bioinformatics study acts a biological literature and developmental data bank for biology related data.

Read Report Overview - https://www.transparencymarketresearch.com/medical-bioinformatics-market.html

Similarly, biomedical informatics is an emerging discipline which defines the study of inventions and implementation of structures, algorithms to improve communication, understanding and managing the medical information. The National Center for Toxicological Research (NCTR) conducts research in bioinformatics and chemo informatics. The bioinformatics tools were created for analysis and integration of genomics, proteomics, metabolomics datasets and transcriptomics.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16382

The growth of global medical bioinformatics market is driven by increasing initiatives and funding, use of bioinformatics in drug discovery and biomarkers. The market is expected to offer opportunities with the introduction and adoption of upcoming technologies such as cloud computing and other sequencing technologies. The global medical bioinformatics market can be segmented by tools approved from Food and Drug Administration (FDA) or European Federation for Medical informatics (EFMI) for further research process.

Medical Bioinformatics market is based on the tools, application and end users.

Request for Analysis of COVID-19 Impact on Medical Bioinformatics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=16382

The global medical bioinformatics market can be segmented based on types of tools and the list of bioinformatics tools approved by FDA are as follows:

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=16382

The global medical bioinformatics market can be segmented by application as follows:

The global medical bioinformatics market can be segmented by end user as follows:

Medical bioinformatics market is segmented into five major regions: North America, Europe, Latin America, Asia Pacific, and Rest of World. North America leads the market followed by the European nations in terms of revenue. Globally, the medical bioinformatics market growth is expected to increase with the demand in development of generic drug development and mode of sequencing the genes in order to have prevalence from various diseases. In 2015, Department of Biomedical Informatics was inaugurated at Harvard Medical School. This was initiated in order to bring quantitative methods and technological development to biomedicine engineering research. According to Harvard Medical School, Department of Biomedical Informatics (DBMI) and research associates planned to break the wall of autism by detecting the disorder in newborns using the same standard of testing device used to check for hearing impairment. According to Food and Drug Administration, collaboration with National Center for Toxicological Research has driven the demand and use of bioinformatics tools such as predicting patient-specific treatment outcomes with in silico tools. Latin America and Asia Pacific regions are anticipated to be the emerging markets in the global medical bioinformatics market during the forecast period. The effective guidelines from EFMI reports the promotion of high standard application and development in medical bioinformatics. Increase in patient population base and rising disease incidences in the Asia Pacific region is expected to fuel the use of bioinformatics tools for research and tests, which is projected to propel the demand in global medical bioinformatics market in the forecast period.

Pre Book Medical Bioinformatics Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=16382&ltype=S

The key players in the global medical bioinformatics market develop bioinformatics tools, and software which is used in drug designing, sequencing methods. Some of the top players in the global medical bioinformatics market are Optra HEALTH, Affymetrix, Inc., Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, Paraxel, Station X and others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Browse More Trending Reports by Transparency Market Research:

Liposomal Doxorubicin Market: https://www.transparencymarketresearch.com/liposomal-doxorubicin-market.html

Local Anesthetic Therapeutics Market: https://www.transparencymarketresearch.com/local-anesthetic-therapeutics-market.html

Preclinical CRO Market: https://www.transparencymarketresearch.com/preclinical-cro-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

See the original post:

Medical Bioinformatics Market shares and strategies of key players - BioSpace

Understanding Neurodegenerative Disease Such as Alzheimers and ALS by Examining the Overlap of microRNAs, Oxidative Stress, and Mitochondria…

Posted on by

Newswise MicroRNAs (miRNAs) have recently been addressed as novel mediators of cellcell communication, being secreted from cells, and are found in many different biological fluids. Such characteristics also make miRNA potential disease biomarkers. Alterations in miRNA expression have been linked to pathological features and these characteristics make miRNA potential disease biomarkers.

In a review article published in the International Journal of Molecular Sciences Special Issue Crosstalk between MicroRNA and Oxidative Stress in Physiology and Pathology 2.0, authors from the Sbarro Health Research Organization (SHRO), at the Center for Biotechnology, Temple University, and the University of L'Aquila, Italy, focused on miRNAs and their role in mitochondrial dysfunction in aging-related neurodegenerative diseases. The article, titled MicroRNAs Dysregulation and Mitochondrial Dysfunction in Neurodegenerative Diseases, explores the potential of both as diagnostic biomarkers and therapeutic targets. These aspects may have important implications for the design of new drugs and therapeutic interventions for these progressive and incurable diseases.

The ms points towards the roles of microRNAs (miRNAs) in mitochondrial dysfunction and neurodegeneration, says Annamaria Cimini of the University of L'Aquila, lead author of the review.

It appears clear that any neurodegenerative disease is characterized by specific miRNAs, with the consequent downregulation or up-regulation of specific genes, says Antonio Giordano, M.D., Ph.D., Founder and Director of the Sbarro Institute for Cancer Research and Molecular Medicine and the Sbarro Health Research Organization (SHRO). However, each condition analyzed shares some miRNA with the others, thus indicating an overlapping of some pathways. This is conceivable if the common presence of oxidative stress and mitochondrial impairment in diverse diseases is considered, Giordano concludes.

The authors would like to acknowledge support from the Ken and Ann Douglas Charitable Foundation.

About the Sbarro Health Research OrganizationThe Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visitwww.shro.org

See the rest here:

Understanding Neurodegenerative Disease Such as Alzheimers and ALS by Examining the Overlap of microRNAs, Oxidative Stress, and Mitochondria...

World-leading Virologists to Speak at COVID-19 International Conference – PRNewswire

Posted on by

WARSZAWA, Poland, Aug. 25, 2020 /PRNewswire/ --On September 30, 2020, opinion leaders in virology and epidemiology will participate in the International Conference COVID-19.

The event will bring together more than 150 specialists: doctors, professors, scientists, leading researchers of the Ebola vaccine, and other viruses. Among the speakers at the conference are Nobel Prize winner in Physiology and Medicine, Australian virologist Peter Doherty and Nobel Prize winner in Chemistry Michael Levitt.

Deputy Director-General of the World Health Organization Zsuzsanna Jakab will make a welcoming speech at the opening of the conference.

Also, speakers at the conference will be:

Oyewale Tomori, Nigeria - Redeemer's University, former President of the Nigerian Academy of Sciences, has studied viral infections including Ebola, yellow fever and Lassa fever.

Pedro Simas, Portugal - The Institute of Molecular Medicine (IMM) at the University of Lisbon, one of the creators of the reusable mask that disables coronavirus upon contact with fabric

Polly Roy, UK - London School of Hygiene and Tropical Medicine, Officer of the Order of the British Empire for service in Virus research.

Alla Mironenko, Ukraine - Gromashevsky Institute of Epidemiology and Infectious Diseases of the NAMS of Ukraine, Doctor of Science, 30 years experience in the field of infectious diseases.

Anupam Varma, India - President of the World Society for Virology, former President of the Indian Virology Society, Honorary Scientist of INSA Emeritus.

The event will be held as online broadcasts on YouTube and Facebook.

The first broadcast will start on September 30 at 6:00 GMT. The conference will be broadcasted in the format of two-hour sessions. Each session will bring together 15 speakers and will end with a block of questions from viewers and participants. One hour break between broadcasts will take place.

In total there will be 10 live broadcasts, the conference will last 30 hours and will end on October 1 at 11:00 GMT.

The final session summing up the event will start on October 1 at 12:00 GMT.

From October 2, 2020, all the video records of the sessions will be available on the conference website and the event channel on YouTube.

The conference is being organized by the Foundation for the support of International Projects based in Warsaw, Poland.

The media are welcome to cooperate with the organizers of the conference.

The partners of the conference will be able to talk to the participants by video call.

More detailed information about the conference and its participants is available on the project website https://www.education-forum.com/ru/covid.

In order to realize any of the 17 goals of sustainable development of the world, including defeating Coronavirus infection (COVID-19), we need to develop a quality education today. Today, COVID-19 does not defeat us, but makes us stop - the virus stops the growth of the global economy, and the global educational and medical community forces us to look for a solution and, most importantly, unite in finding a solution to defeat COVID-19.

The unification of the global medical community in the fight against COVID-19 once again confirms the correctness of the path we have chosen to achieve all the goals of sustainable development of the world.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE COVID-19 International Conference

https://www.education-forum.com/ru/covid

Read more from the original source:

World-leading Virologists to Speak at COVID-19 International Conference - PRNewswire

Identifying emerging diseases focus of new international collaboration – Washington University School of Medicine in St. Louis

Posted on by

Visit the News Hub

School of Medicine to become 1 of 10 sites under new Centers for Research in Emerging Infectious Diseases

Washington University School of Medicine in St. Louis is one of 10 sites and a coordinating center forming the Centers for Research in Emerging Infectious Diseases, funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH). The centers are a coordinated network with collaborators in different regions across the globe where emerging and re-emerging infectious disease outbreaks have proven likely to occur.

Researchers at Washington University School of Medicine in St. Louis are establishing a new international collaboration that aims to help scientists prepare for the next pandemic and, perhaps, provide insight into the current one.

The School of Medicine is one of 10 sites and a coordinating center forming the Centers for Research in Emerging Infectious Diseases, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Washington Universitys center will be supported by a five-year, $8.1 million grant.

The Centers for Research in Emerging Infectious Diseases (CREID) is a coordinated network with centers that will each have collaborators in different regions across the globe where emerging and re-emerging infectious disease outbreaks have proven likely to occur. The Washington University-led center includes researchers at La Jolla Institute for Immunology in San Diego and international collaborators in China, Hong Kong, Nepal and Ethiopia. In recent years, these regions have seen the emergence of multiple dangerous viruses, including H5N1 influenza, SARS, MERS and, most recently, SARS-CoV-2, the virus that causes COVID-19.

We want to be able to respond quickly and effectively to the emergence of a new infectious disease, said David Wang, PhD, principal investigator of the new center at Washington University. If we can understand the source of the infection, how it spreads and how it affects people, we have a better shot at preventing a new infectious disease from becoming a major threat to global public health.

Multidisciplinary teams of investigators will conduct surveillance of potential sources of new diseases and the local populations at risk of infection. The researchers will study transmission, disease progression, and immunologic responses in the host, and will develop diagnostic tests and animal models of the new diseases for improved detection of important emerging pathogens and the methods by which they spread.

Such information could help predict which new infectious diseases are at highest risk of reaching pandemic status and aid in efforts to understand the new disease and prevent its spread.

In addition to Wang, a professor of molecular microbiology, and of pathology & immunology, key researchers at Washington Universitys center include Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine; Jacco Boon, PhD, an associate professor of medicine; and Scott A. Handley, PhD, an associate professor of pathology & immunology.

The international centers will monitor local populations for the most common red flags of an emerging infection: respiratory disease, inflammation of the brain, and unexplained fever. The researchers will study patient samples to look for new viruses or other microbes with the potential to cause disease. At the same time, investigators will survey local livestock, mosquitoes and ticks to help identify the potential origins of viruses that could be infecting people in a particular region.

The Washington University researchers will focus on the molecular biology and genetics of emerging viruses and on developing animal models, such as mice and other rodents, to help study potentially dangerous viruses, understand how they spread and set the stage for developing treatments.

If we find a new virus that we want to prioritize, we will develop diagnostic tests, and tools to study the virus and will begin to develop treatments, such as therapeutic antibodies, Wang said. We could use our animal models to test possible new drugs. We also will fine tune plans so that we are quick to respond to new emerging outbreaks, such as SARS-CoV-2, first reported in Wuhan, China.

Weve prioritized studies of COVID-19 at the university, Wang added. Were sequencing the genomes of SARS-CoV-2 viruses to understand the transmission and evolution of the virus that is circulating in the St. Louis region. Were also trying to understand how the proteins that the virus makes contribute to the severity of the infection.

The new centers are prioritizing the study of families of viruses that have shown the most potential to impact humans, including coronaviruses (SARS-CoV and MERS-CoV), paramyxoviruses (measles and respiratory syncytial virus), flaviviruses (West Nile, Zika and dengue) and alphaviruses (chikungunya virus), among others.

There are clear sets of viral families that we are most concerned about because they have the highest likelihood of causing major disease in humans, Wang said. At the same time, were definitely looking for everything with our surveillance studies. Every viral family has the potential to be highly dangerous. We hope this program will help identify those infectious diseases most likely to cause major problems, so we can take steps to lessen the impact.

For more information, visit: https://creid-network.org

This work is supported by the NIAID of the NIH, grant number U01AI151810.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Continued here:

Identifying emerging diseases focus of new international collaboration - Washington University School of Medicine in St. Louis

COVID-19 & Healthcare: Personalized Medicine is the Future – The National Law Review

Posted on by

Thursday, August 27, 2020

In this episode, Foley PartnersJudy WaltzandAntoinette Konskitalk withEdward Abrahams, the President of the Personalized Medicine Coalition, to discuss the issues facing personalized medicine and how the concepts underpinning the field may be applied to diagnose and treat COVID-19.

We encourage you to listen to thepodcast in its entirety.

Following is a transcript of this podcast. Please feel free to download aPDF version here.

Please note that theinterview copy below is not verbatim. We do our best to provide you with a summary of what is covered during the show. Thank you for your consideration, and enjoy the show!

Personalized or precision medicine is the field of medicine that finds the best treatment for each patient at the right time. Physicians use diagnostic tests, medical history, circumstances, and values, as well as information from prior patient therapies, to prevent disease and develop targeted therapies that can expedite a patient's treatment and recovery.

The Personalized Medicine Coalition, or PMC, is an advocacy and educational group that represents innovators, scientists, patients, providers, and payers to promote the understanding and adoption of personalized medicine concepts, services, and products. Dr. Edward Abrahams is the president of the PMC and has charted its growth from its original 18 founding members in 2004 to more than 200 members today.

I am pleased to have Ed as our guest to explore issues facing personalized medicine and how its concepts and emerging research may be applied to diagnose and treat COVID-19. Ed, thank you so much for being with us here today. Did I hit the mark on precision medicine? Is there anything you would like to add by way of introduction to yourself or the PMC?

I think you have defined personalized medicine very well indeed. Let me begin by noting, as you just did, that I have never met a patient who did not prefer getting the right medication the first time, rather than going through a process of trial and error because the right diagnosis could not be made in advance of selecting the right therapy.

The good news is that we have many more molecular diagnostics today to target the right treatments to the right patients at the right time, as is often said. But personalized medicine also promises lower costs for systems that incorporate the tests and treatments underpinning the field into their clinical work streams. This is very important. By becoming more efficient with targeted therapeutics and avoiding costly interventions that don't work, personalized medicine can help these systems save money, and, at the same time, provide better outcomes for individual patients.

In other words, and this is terribly important in today's context of constricted resources for health care, with personalized medicine, we can enjoy the benefits of innovation and reduce costs. But we have to be smart about how we develop these opportunities. At present, we have only anecdotal evidence that personalized medicine can deliver both clinical and economic benefits, which is why PMC is doing the research to demonstrate that even if individual therapies come with high price tags, as many in fact do, they can and will produce cost savings if we target them to only those patients who will benefit.

That, in brief, is the real promise of personalized medicine. We believe personalized medicine can provide tremendous value, not only to patients, but also to the systems and countries that in fact have the courage to implement it.

Thank you so much for that explanation and background on personalized medicine and how it is being used today to treat and prevent disease. Ed, for me, one of the highlights of the year is the publication of PMC's annual report that summarizes the key advances the industry has made over the past year. When will the 2020 edition be released, and can you give us a preview of what to expect?

Within the next eight weeks, the Personalized Medicine Coalition will publish the sixth edition ofThe Personalized Medicine Report. We used to call itThe Case for Personalized Medicine, but we now believe that the case has been made.

The report is our effort to define the field by explaining personalized medicine's opportunity, documenting its status, and discussing the challenges it faces. It's a widely read report that is written for laymen, particularly policymakers at federal agencies and on Capitol Hill.

The sixth edition will, for example, show that in 2008, there were only five personalized medicines, which we define as therapeutics with biomarker strategies on their labels, on the market. Today, there are over 250, so you can see there's been enormous progress over these past 10 years or so.

While most of these products are in oncology, we have also seen progress in other indications as well, including cardiovascular illness, depression, and especially rare diseases. The report will also show that today there are 75,000 genetic testing products on the market, up from fewer than 66,000 in 2016. In other words, this is an exploding field.

Also new in this report are discussions of how advanced analytics, artificial intelligence, and machine learning are yielding new insights about how other biological and environmental factors, in addition to genetics, influence a patient's disease risk and response to various treatments, thus opening the door to preventive medicine, one of personalized medicines most important if as yet unrealized promises.

The report documents how, by targeting effective treatments to those patients who benefit, personalized medicine can achieve key goals for patients and health systems. It can shift the emphasis in medicine from reaction to prevention with emerging technologies like liquid biopsies, which may be able to detect cancer before any symptoms occur. This is tremendously important and a great promise. It may reduce trial-and-error prescribing, which patients would absolutely love.

Personalized medicine can also cut the number of adverse drug reactions, which right now are the third or fourth largest cause of death in the United States. It can use cell-based or gene therapy to replace or circumvent molecular pathways associated with disease, thereby offering cures where none had existed before. It can reveal additional targeted uses for medicines and drug candidates. It will obviously increase patient adherence to treatment, as patients will be more likely to stay on medications that don't have dangerous side effects, for example.

Personalized medicine will also reduce high-risk invasive procedures, which it already has done in say, kidney transplants, for example. It will help move patient-physician engagement toward patient-centered care. And finally, as I mentioned, it could and should reduce the overall cost of health care.

The report makes the argument that outstanding challenges in regulation, reimbursement, and clinical adoption slow our efforts to capitalize on advances made possible by personalizing treatments. Overcoming these obstacles, as we write, will require a collaborative effort to keep up with the pace of progress in science and technology. And this is in fact the overall mission of the Personalized Medicine Coalition.

At the end of the dayand you mentioned this a bit in your commentsfor personalized medicine to be a success and available to patients, it has to be adopted by the clinicians. How does that happen, and are there obstacles to that success?

This is a key thrust of the Personalized Medicine Coalition because we are learning that clinical adoption is a much slower process than patients want and expect. For example, PMC will publish a study this week documenting that medically appropriate genomic testing is quite inconsistent across the United States.

That means, for example, that some patients in cancer are not getting available treatments they need. The study shows that coverage and reimbursement strategies are not the only barriers to personalized medicine, as you might expect. Other barriers include lack of awareness among providers and patients, not to mention socioeconomic factors, including distance and access issues.

In medicine, it doesn't necessarily follow that if you build it, they will come. There are many mediators along the way from discovery and development to adoption. We also know from another PMC-commissioned study of the value of genomic testing in cancer care, for example, that many patients who are eligible for effective targeted therapies, as determined by genomic sequencing of their tumor, still do not receive the best treatment option based on the results.

This practice gap can be attributed to the limitations in the availability and interpretation of test results, sample processing constraints, limited access to targeted therapies, and especially lagging awareness of the rapidly evolving field of personalized medicine among physicians and other providers.

We demonstrate in this study that if all patients who were eligible to receive a targeted treatment actually received it, the cost-effectiveness of genomic sequencing, which is sometimes alleged to be too high, would significantly improve. In short, along with public policy, we know that the downstream issues focused on clinical adoption are extremely important and must be addressed.

We are in a continuing debate with respect to drug pricing in the United States. How does that debate impact the future of personalized medicine and how would you address or make some recommendations as to how we price our drugs?

That's a very important question because as you know, the drug pricing debate has gripped public attention. But we are not considering all ramifications. The debate has particular implications for the development of personalized medicines, which tend to be more expensive but may together have a positive impact on the health care system and on overall costs.

We have to ensure that innovative products remain accessible, including to those who cannot afford them. But we also have to be careful not to remove the incentives to discover and develop those products in the first place, which I am afraid that price controlsno matter how they are implementedwould do. That is to say, they would stifle innovation. Drug development is a risky business. There are no guarantees. If we move or decrease the financial incentive to find new cures to unmet medical needs, it follows that we're going to see fewer interventions.

Late last month, President Trump issued an executive order to tie the prices paid for physician-administered drugs, many of which are personalized medicines, to those that are paid in other countries. That may be politically popular because those other countries pay less. But the policy, if implemented, will have disastrous unintended consequences for the development of say, new cell-based therapies, gene therapies, and targeted medicines that are only now reshaping health care in ways no one thought possible ten years ago.

This is so because there are incentives in place to encourage the development of groundbreaking therapies. It's important to understand that when a pharmaceutical company invests in, say, finding a one-shot cure for spinal muscular atrophya rare and debilitating disorder that affects fewer than 25,000 people in the United Statesit does so without any guarantee of success, and it does so also with very high up-front costs that must be recovered. If the company that develops the cure cannot get a return on its investment, it's unlikely to take these big risks upon which patients depend. Long story short, patients will suffer and the costs of providing carenot curesfor those patients will remain higher than they could be.

I'd like your opinion on a topic of current urgent and global concern. Today, we are challenged medically and economically with the COVID-19 pandemic. How have the principles of personalized medicine been applied to diagnosing and treating COVID-19?

I actually believe that the principles of personalized medicine that emphasize stratified responses, even when it comes to public health, have significant implications for diagnosing and treating COVID-19. Those principles, I believe, should inform future interventions to stem this terrible pandemic that has already killed over 170,000 people in the United States alone.

I don't think these principles are being adequately considered as part of the debate. PMC looks forward to introducing those principles, because they're so very important if we're going to effectively address this pandemic.

First, we have been very slow to develop and deploy real-time diagnosticsthe backbone of personalized medicine. These diagnostics give us the tools to determine who is at risk, so we don't have to put in place one-size-fits-all public health responses, including closing down whole economies, when that might not be necessary if we knew who had the disease or who was likely to get the disease.

To date, we have not been able to target long-term prevention and treatment plans to the most at-risk populations, which would be enormously helpful in reopening economies, which we would obviously like to do sooner than later.

Second, and equally important, we know that the coronavirus expresses itself differently among different populations. For example, older men, racial and ethnic minorities, and those with particular underlying conditions seem to be more vulnerable to disease. It behooves us, therefore, to understand the molecular and environmental reasons for this differentiated response, and to develop and deploy therapies and vaccines that are targeted to those who are in need.

Today, we are looking for one-size-fits-all solutions because there's an urgency to find one. But eventually, scientists in my opinion are going to recognize that, because not everyone responds the same, different medicines are going to have to be developed to treat COVID-19 and other viruses.

We've already seen this in AIDS, and so I don't think the coronavirus is going to be different. We have to be really smart about how we address this pandemic. By the way, on September 3rd, PMC is organizing a virtual seminar, titledCOVID-19 and Personalized Medicine: Current Status and Lessons Learned. It is free, and if you want to register, you can do so on ourwebsite.

Ed, thank you so much for being with us today, and as we wrap up, I'd like to invite you to make any closing remarks or comments on the topics we covered today.

I'd really like to thank you both for your loyal support to the Personalized Medicine Coalition, and for giving me the opportunity to discuss these very important issues with your audience. I hope people will pay attention to personalized medicine. We believe it represents the future, and we also believe that if we invest in it, if we come together collaboratively as a community, we can have a health care system that we deserve based upon the developments in science and technology, which have never been more promising. Again, thank you for your attention, and I look forward to working with you and everybody on this podcast to move this field forward. It's not going to happen by itself.

Continue reading here:

COVID-19 & Healthcare: Personalized Medicine is the Future - The National Law Review

Impact of exogenous antithrombin on low molecular weight heparin anti-Xa activity assays in a pediatric and young adult leukemia and lymphoma cohort…

Posted on by

Low molecular weight heparin (LMWH) remains the most commonly prescribed pediatric anticoagulant. There is debate whether LMWH anti-Xa assays with or without exogenous antithrombin (AT) best reflect anticoagulation effect, and how much discrepancy exists between assay types.We assessed the effect of variable AT activity on LMWH anti-Xa levels in plasma samples from anticoagulated pediatric and young adult acute lymphoblastic leukemia and lymphoma (ALL/L) patients, using two instruments and their commercial kits with and without exogenous AT (ie, four platforms).We analyzed LMWH anti-Xa levels on 60 plasma samples with known AT activity from 12 enoxaparin-treated ALL/L patients, using four commercial kits from Siemens and Stago containing AT or not, on Siemens BCS and Stago STA R Max, respectively.Of 236/240 samples with interpretable results, mean AT activity was 80% (46-138%). Correlation was acceptable for published kit ranges of LMWH anti-Xa levels when comparing kits containing AT (r=0.82, P<.0001), or not (r=0.93, P<.0001), and within a manufacturer (Berichrom to Innovance, r=0.92, P<.0001; Stachrom to STA-Liquid Anti-Xa r=0.98, P<.0001). LMWH anti-Xa levels were lower in platforms without added AT (P<.0001). For Stago kits, this effect increased when AT<70% (P=.001, n=19, mean 56%). Assay variability, measured as mean percent difference, was less pronounced with Stago kits (14.7%, n=49) than Siemens (41.9%, n=50).Although LMWH levels from anti-Xa assays with added AT trend higher than in those without, correlation was fairly good between platforms in pediatric ALL/L plasmas, even when AT activity was <70%. 2020 Wiley Periodicals LLC.

PubMed

Link:

Impact of exogenous antithrombin on low molecular weight heparin anti-Xa activity assays in a pediatric and young adult leukemia and lymphoma cohort...

4D Molecular Therapeutics Appoints Susannah Gray to Board of Directors – BioSpace

Posted on by

Aug. 27, 2020 11:00 UTC

EMERYVILLE, Calif.--(BUSINESS WIRE)-- 4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced the appointment of Susannah Gray to the Board of Directors. Ms. Gray brings more than 30 years of biopharmaceutical experience specifically in corporate finance and capital markets roles, most recently serving as EVP, Finance & Strategy of Royalty Pharma Management, LLC.

Susannahs extensive knowledge and experience in corporate finance and capital markets brings a valuable perspective to 4DMT. said David Kirn, MD, co-founder, chairman and chief executive officer of 4DMT. Susannahs appointment reflects our commitment to augmenting the capital markets expertise on the 4DMT board as we contemplate the capital required to support the clinical and preclinical development of our product candidates, two of which have recently entered the clinic. We look forward to benefiting from Susannahs extensive experience as we advance 4DMTs next-generation gene therapy programs.

Prior to joining 4DMT, Ms. Gray spent 14 years as executive vice president and chief financial officer of Royalty Pharma before retiring in 2019 just ahead of the Companys initial public offering. At Royalty Pharma, Ms. Gray led the Companys efforts to maximize its financial capabilities. She spearheaded the Companys successful implementation of a $2.3 billion credit facility in 2007 and has helped raise over $1.4 billion in equity capital for the Company. Prior to joining Royalty Pharma, Ms. Gray had a 14-year career in investment banking. In her most recent role, she was a managing director and the senior analyst covering the healthcare sector for CIBC World Market's high yield group from 2002 to 2004. She worked in a similar capacity at Merrill Lynch prior to joining CIBC World Markets. Ms. Gray joined Merrill Lynch in April 1999 after nine years at Chase Securities (a predecessor of JP Morgan), working in various capacities within the high yield and the structured finance groups. Ms. Gray received a BA with honors from Wesleyan University and holds an MBA degree from Columbia University.

I am excited to be part of this outstanding team at this key moment in the companys trajectory, said Susannah Gray. 4DMTs next-generation Therapeutic Vector Evolution platform enables the development of gene therapies with improved therapeutic profiles, enabling the company to pursue previously untreatable patient populations and to address a broad range of both rare and large market diseases. I look forward to working closely with the 4D team and supporting its mission to bring optimized gene therapies to patients.

About 4DMT

4DMT is a clinical-stage precision gene medicine company harnessing the power of directed evolution to unlock the full potential of gene therapy for rare and large market diseases in lysosomal storage diseases, ophthalmology, neuromuscular diseases, and cystic fibrosis. 4DMTs proprietary Therapeutic Vector Evolution platform enables a disease first approach to product discovery and development, thereby empowering customization of AAV vectors to target specific tissue types associated with the underlying disease. These proprietary and optimized AAV vectors are designed to provide targeted delivery by routine clinical routes of administration, efficient transduction, reduced immunogenicity, and resistance to pre-existing antibodies -- attributes that could enable the development of gene therapies that overcome known limitations of conventional AAV vectors. 4DMT vectors are designed to exhibit improved therapeutic profiles that enable the company to pursue previously untreatable patient populations and to address a broad range of rare and large market diseases.

4D Molecular Therapeutics, 4DMT, Therapeutic Vector Evolution, and the 4DMT logo are trademarks of 4DMT.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200827005202/en/

See original here:

4D Molecular Therapeutics Appoints Susannah Gray to Board of Directors - BioSpace

Oncocyte Announces Addition of Experienced Healthcare Executive, Jennifer Carter, MD, MPH, MBA to Board of Directors – GlobeNewswire

Posted on by

IRVINE, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced the appointment of Jennifer Levin Carter, MD, MPH, MBA to its Board of Directors.

Dr. Carter is a true pioneer in applying precision medicine in the world of oncology, said Cavan Redmond, Chairman of the Board of Oncocyte. Her work at N-of-One was instrumental in advancing a new paradigm in cancer treatment which harnessed the power of molecular panels to correlate, and ultimately improve patient outcomes. Dr. Carters deep expertise and understanding in this domain will be invaluable at Oncocyte as we push forward into the world of immunotherapy to leverage targeted response prediction and patient selection in both the clinic and Pharma services opportunities.

Dr. Carter added, Im honored to join the Board of Directors at Oncocyte and believe that their growing suite of molecular tests has the potential to markedly improve patient outcomes through a precision approach that identifies the right treatment for each patient. I look forward to leveraging my experience in developing molecular guided treatment strategies to advance Oncocytes rapid growth and physician adoption. Their strategic approach in identifying critical underserved decision points for patients has led to the development of two important tests for response prediction in NSCLC and now for immunotherapy, and I am thrilled to collaborate with the board and management as we work to broaden the patient population and partners that will benefit from these critically important tests.

Dr. Jennifer Levin Carter is a healthcare executive, board member and entrepreneur and was most recently VP, Head of Precision Health at Integral Health, A Flagship Pioneering company. She has founded and served as CEO at healthcare companies including N-of-One, Inc., where she was CEO from 2008-2012 and Chief Medical Officer from 2012 until its acquisition in 2019. At N-of-One, Dr. Carter led the creation of award-winning solutions that delivered novel treatment strategies to hundreds of thousands of patients with cancer globally.

In addition to her board appointment for Oncocyte, Jennifer serves as a Director of DFP Healthcare Acquisitions Corp.; on the Board of Directors of HouseWorks, LLC., a home healthcare company, eCaring, Inc., a digital health home care platform and Target Cancer Foundation where she has worked closely with the Executive Director on the design and launch of a precision medicine clinical trial for patients with rare cancer. She is a Founding Strategic Board member of XSphera Biosciences, Inc., an Ex Vivo Immuno-oncology diagnostic company and on the Directors Advisory Board at Smilow Cancer Hospital at Yale University. She is an Advisor and has consulted for numerous healthcare and life sciences startups and venture-backed companies on strategy, product development, business model design and fund raising.

About Oncocyte CorporationOncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.

DetermaRx and DetermaIO are trademarks of Oncocyte Corporation.

Oncocyte Forward Looking StatementsOncocyte cautions you that this press release contains forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates, may, and similar expressions) are forward-looking statements. These statements include those pertaining to the commercial launch of DetermaRx, development of DetermaIO, unexpected expenditures or assumed liabilities or other unanticipated difficulties resulting from acquisitions, implementation and results of research, development, clinical trials and studies, commercialization plans, future financial and/or operating results, and future opportunities for Oncocyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on our financial and operational results, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to our supply chain, the need and ability to obtain future capital, maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients use of any diagnostic tests we commercialize, and risks inherent in acquisitions such as failure to realize anticipated benefits, unexpected expenditures or assumed liabilities, unanticipated difficulties in conforming business practices including accounting policies, procedures and internal controls, greater than estimated allocations of resources to develop and commercialize technologies, or failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the Risk Factors and other cautionary statements found in Oncocytes Securities and Exchange Commission filings, which are available from the SECs website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor ContactBob YedidLifeSci Advisors, LLC646-597-6989bob@lifesciadvisors.com

Media ContactCait Williamson, Ph.D.LifeSci Communications, LLC656-751-4366cait@lifescicomms.com

Here is the original post:

Oncocyte Announces Addition of Experienced Healthcare Executive, Jennifer Carter, MD, MPH, MBA to Board of Directors - GlobeNewswire

HTG Molecular Diagnostics Inc. (HTGM) market price of $0.37 offers the impression of an exciting value play – The InvestChronicle

Posted on by

HTG Molecular Diagnostics Inc. (HTGM) is priced at $0.37 after the most recent trading session. At the very opening of the session, the stock price was $0.4006 and reached a high price of $0.4056, prior to closing the session it reached the value of $0.40. The stock touched a low price of $0.39.

Recently in News on August 18, 2020, HTG Introduces Oncology Applications and Expands Analytics Capabilities with Release of New Software Update. HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the commercial release and immediate availability of HTG EdgeSeq Reveal version 3.0, adding additional applications and software functionalities. You can read further details here

HTG Molecular Diagnostics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $0.9200 on 06/22/20, with the lowest value was $0.2671 for the same time period, recorded on 04/03/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, HTG Molecular Diagnostics Inc. shares are logging -63.61% during the 52-week period from high price, and 38.97% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $0.27 and $1.02.

The companys shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1462310 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the HTG Molecular Diagnostics Inc. (HTGM) recorded performance in the market was -43.52%, having the revenues showcasing -31.36% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 31.79M, as it employees total of 108 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.5377, with a change in the price was noted +0.0822. In a similar fashion, HTG Molecular Diagnostics Inc. posted a movement of +28.34% for the period of last 100 days, recording 4,609,364 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity The total Debt to Equity ratio for HTGM is recording 0.91 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.81.

Raw Stochastic average of HTG Molecular Diagnostics Inc. in the period of last 50 days is set at 1.88%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 2.81%. In the last 20 days, the companys Stochastic %K was 5.74% and its Stochastic %D was recorded 5.37%.

Considering, the past performance of HTG Molecular Diagnostics Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -43.52%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -27.47%, alongside a downfall of -58.16% for the period of the last 12 months. The shares increased approximately by -13.34% in the 7-day charts and went up by -36.46% in the period of the last 30 days. Common stock shares were lifted by -31.36% during last recorded quarter.

More here:

HTG Molecular Diagnostics Inc. (HTGM) market price of $0.37 offers the impression of an exciting value play - The InvestChronicle

STRUCTURAL BIOLOGY AND MOLECULAR MODELING TECHNIQUES MARKET PREDICTED TO ACCELERATE THE GROWTH BY 2017-2025 – Scientect

Posted on by

Structural Biology and Molecular Modeling Techniques Market: Overview

The global structural biology and molecular modeling techniques market is a novel conception in the global healthcare sector and has already made key contributions in obtaining remedies to a number of diseases. The structural biology and molecular modeling field is concerned with how various molecules in biological compounds are arranged and how the peculiarity of the arrangement affects the nature of the compound. The field also studies how alterations in the structure of the compounds affect their nature and how the position of each part of the structure is linked to the overall nature of the compound.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1280

The structural biology and molecular modeling techniques market has significant potential due to the rising prevalence of chronic diseases. Improving the quality of medicine and healthcare in general has been a key focus of governments across the world in recent years due to the rising volume of patient demographics and the growing geriatric population. This has driven consistent investment in the medical research in recent years, making steady development of the structural biology and molecular modeling techniques market likely in the near future.

North America is likely to remain the leading regional market for structural biology and molecular modeling techniques in the coming years due to the strong emphasis on the widespread incorporation of healthcare IT and the presence of strong investment channels for the medical research field as well as several key healthcare industry players. The presence of advanced technological framework supporting research in complementary areas of the structural biology and molecular modeling techniques market, such as genomics, is also likely to be a key driver for the North America structural biology and molecular modeling techniques market in the coming years.

Global Structural Biology and Molecular Modeling Techniques Market: Snapshot

The global structural biology and molecular modeling techniques market has been thriving due to the high prevalence of chronic diseases. The market is also gaining a strong foothold across the globe as treating these diseases is becoming increasingly difficult due to the acquired drug resistance. In the light of these developments, research and development activities using structural biology and molecular modeling techniques have been in full swing. The increasing focus on improving the quality of medicines and ensuring patient recovery and safety has augmented the demand for various structural biology and molecular modeling techniques. The demand for these techniques is projected to soar as the need to reduce drug failure is an immense one amongst healthcare institutes.

The report answers questions pertaining to the size of the global market by the end of the forecast period, leading segments, and players amongst others. The report is a comprehensive outlook of the global market and it presents key market insights for readers with absolute objectivity.

Global Structural Biology and Molecular Modeling Techniques Market: Drivers and Trends

The rapid pace of technological developments and innovations have been exceptionally supportive of the global market over the past few years. Both these aspects have authenticated the sophisticated models that help in the accurate determination of cellular interactions and function, which in turn helps in identifying the problem area and a subsequent solution. The wide range of structural biology and molecular modeling techniques are expected to find tremendous scope in the area of drug discovery. These techniques will prove to be important in identifying the missing pieces that limit the process of drug discovery, thereby resulting in high success rates.

Adoption of these techniques in pharmacogenomics and pharmacogenetics are also expected to prove beneficial to the overall growth of the market. Analysts project that increasing incidences of diseases where several drugs cannot be administered to the patient will prove to be a lucrative ground for the global structural biology and molecular modeling techniques market.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1280<ype=S

Global Structural Biology and Molecular Modeling Techniques Market: Regional Outlook

Spread over regions such as North America, Asia Pacific, the Middle East and Africa, Europe, and Latin America, the global structural biology and molecular modeling techniques market has truly made its market in North America. The higher understanding of diseases and empathy toward managing them with supportive regulatory policies has been North Americas winning strategy for the past few years. Increasing funding for research and development of novel drugs is expected to favor this regional markets growth in the coming years as well.

On the other hand, increasing expenditure on IT, healthcare infrastructure, and research organizations in Asia Pacific is also expected to open up new avenues for growth for the overall market. Furthermore, the rising standard of living of people in developing countries, improving GDPs, and better access to healthcare are also expected to fuel the demand for structural biology and molecular modeling techniques in Asia Pacific.

Global Structural Biology and Molecular Modeling Techniques Market: Competitive Landscape

The key players identified by the research analysts are Dassault Systemes, Agile Molecule, Acellera Ltd., Bioinformatic LLC, Affymetrix, Agilent Technologies, Inc., Illumina, Bruker Daltonics Inc., Biomax Informatics AG, Chemical Computing Group, and CLC bio. The report points out that the global market is expected to witness intense competition in the coming years. However, to stay ahead of the competition, several players are expected to focus on mergers and acquisitions, investments for novel drug development, and technological advancements.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1280

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Link:

STRUCTURAL BIOLOGY AND MOLECULAR MODELING TECHNIQUES MARKET PREDICTED TO ACCELERATE THE GROWTH BY 2017-2025 - Scientect

Waveland community group says $2500 donation will widen impact – Journal Review

Posted on by

Nick Hedrick | nhedrick@jrpress.com

WAVELAND As seventh-grader Emery Allen, who belongs on Broadway, stepped up to the town parks stage Friday evening with a medley of show tunes, vendors sold their wares before closing down the farmers market for the season.

The small town summer evening was put on by nonprofit community group Waveland Strong, which will further its mission of promoting the town thanks to a local farmers donation.

Darren Simpson, who lives east of Waveland, presented the volunteers with a $2,500 grant from the Americas Farmers Grow Communities program, sponsored by the Bayer Fund. Simpson said he directed the money to the group as a way to help more than one organization.

Waveland Strong supports local churches and Montgomery County 4-H.

Im very glad to see that theyre doing things that needs to done around the community. They really stepped up when we had a hole [in the community] I guess you could say, Simpson said after presenting the check.

Theyre doing a lot of good things with the talents they have.

The group is waiting on other grant funding, which will help determine how the donation is spent, Waveland Strong president Troy Phillips said.

With Parke Countys Covered Bridge Festival canceled this year due to the coronavirus pandemic, the group will look for ways to support vendors who set up at the event. A Christmas bazaar is already in the works.

A family game night will be held Sept. 18, followed by a progressive dinner on Sept. 26. A community garage sale is set for October.

The group has also carried out a series of beautification projects, including at the park.

Weve created a presence, and this is the kind of go-to organization in town, member Gina Haile said. They like what were doing and they want to help.

See the original post here:

Waveland community group says $2500 donation will widen impact - Journal Review

Global Human Augmentation Market : Industry Analysis and Forecast (2019-2027) By Technology, Devices, and Region. – Galus Australis

Posted on by

Global Human Augmentation Market size was US$ 70.9 Bn in 2019 and is expected to reach US$ XX Bn by 2027, at a CAGR of 23.9% during the forecast period.

Request For View Sample Report Page :@https://www.maximizemarketresearch.com/request-sample/66366/

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Market Definition

Human augmentation is the latest advanced technology that intends to augment the mental and physical capabilities of the human body by using artificial, scientific, and natural technology. It is also called as human 2.0 and human performance enhancement (HPE).

Market Dynamics

A surge in the exploration and adoption of marketable and innovative applications for human augmentation technology byentrepreneurs, engineers,policymakers, andresearchers across the globe is a major driving factor behind the growth of the market. Increasing requirements of augmented technologies such as augmented intelligence to perform several tasks without replacing humans, increasing demand of wearable augmentation products, rising adoption of human augmentation in the healthcare sector, growing advancements in technologies such as human genetic engineering, 3D bioprinting and in neurotechnology, rising adoption of IoT, smart tech devices and rising advancements in robotics automation, andartificial intelligence technologies are expected to improve the growth of the marketduring the forecast period.

Nevertheless, high costs associated with human augmentation devices, social, legal, and ethical concerns, lack of skilled personnel to handle human augmentation devices, and rising risks of identity and data breaches are some of the restraining factors that could hamper the growth of the market.

Global Human Augmentation Market: Segmentation AnalysisBy technology, wearable augmentation segment dominated the market in 2019 and is projected to witness fast growth at CAGR of XX% during the forecast period. Growing adoption of smart wearable devices such as wrist-wear, eye-wear, foot-wear, neck-wear, and body-wear devices such as smart glasses, HMDs, HUDs, smartwatches, smart jewellery, and smart clothes by consumers across the globe is attributed to the growth of the market. MMR expected that industrial wearable human augmentation devices will witness huge demand in the North American market in the coming years due to its portability, efficiency, and convenience. Increasing the adoption of medical wearable devices in the healthcare industry is propelling the growth of the market.

Some examples of wearable human augmentation:

There are numerous wearable augmentation devicespresent in the global market. Growing adoption of these devices by consumers across the globe to enhance their physical capabilities such as low vision is impelling the growth of the market. Some of the examples of these devices are as follows:

Do Inquiry Before Purchasing Report Here: @https://www.maximizemarketresearch.com/inquiry-before-buying/66366/

ESight- It is a wearable augmentation device and its appearance looks the same as glasses. This device provides blind persons with the capability to see their surrounding environment. Exoskeletons- It is a mechanical wearable device that is used to wear on the outside of the body. This is the type of industrial wearable device which is used by human workers to lift 200 pounds of heavy machinery. Teslasuit- It is wearable smart clothing or outfit which is used to provide haptic feedback, to track the consumers movements and to control the consumers temperature.

Global Human Augmentation Market: Regional Analysis

Region-wise, North America dominated the market in 2019 and is expected to maintain its dominance at a CAGR of XX% during the forecast period. The US and Canada are the major contributors behind the growth of the market in the region. The growth is attributed to the growing and early adoption of human augmentation devices by various end-users across the region.

Increasing investments in artificial intelligence technologies, increasing demand for wearable augmentation devices from the healthcare industry, and growing technological advancements in virtual reality are driving the growth of the market in the NA region.

The objective of the report is to present a comprehensive analysis of the Global Human Augmentation Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Human Augmentation Market dynamics, structure by analyzing the market segments and projects the Global Human Augmentation Market. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Human Augmentation Market make the report investors guide.The Scope of Global Human Augmentation Market

Global Human Augmentation Market, By Technology

Wearable Virtual Reality Augmented Reality Augmented Intelligence Exoskeleton Intelligent Virtual AssistantsGlobal Human Augmentation Market, By Device

Body Worn Non-body WornGlobal Human Augmentation Market, By Region

North America Europe Asia Pacific South America Middle East & AfricaGlobal Human Augmentation Market, Key Players

Google Inc Samsung Electronics Co. Ltd Ekso Bionics Holdings Inc Vuzix Corporation Garmin Fossil Group Inc B-Temia Inc Casio Magic Leap Inc Rewalk Robotics Inc Polar Electro P&S Mechanics Jawbone Inc Life Sense Group B.V Atoun Mobvoi Rex Bionics Goqii Guangdong BBK Electronics Co. Ltd Atheer Inc

Browse Full Report with Facts and Figures of Human Augmentation Market Report at:https://www.maximizemarketresearch.com/market-report/global-human-augmentation-market/66366/

Major Table Human Augmentation Market of Contents Report

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: Maximize Market Research Pvt. Ltd.

Email: [emailprotected]

Contact: +919607065656 / +919607195908

Website: http://www.maximizemarketresearch.com

Read the original:

Global Human Augmentation Market : Industry Analysis and Forecast (2019-2027) By Technology, Devices, and Region. - Galus Australis

Three initiatives that would authorize and tax gambling at racetracks in Nebraska will not make the November ballot – Ballotpedia News

Posted on by

On August 25, 2020, Nebraska Secretary of State Bob Evnen (R) announced that three initiatives that would authorize and tax gambling at racetracks in Nebraska would not make the ballot after three NebraskansDr. Richard Loveless and Ann and Todd Zohnersubmitted written objections regarding the ballot language of the initiatives. The objections were filed on August 7 after Keep the Money in Nebraska, the campaign behind the three initiatives, submitted over 465,000 signatures on July 2 for the three petitions. Secretary Evnen determined that all three petitions were not legally sufficient, thereby disqualifying them from the November ballot. Keep the Money in Nebraska plans to appeal the secretary of states decision.

Constitutional Amendment to Allow Laws Authorizing Gaming at Racetracks Initiative: The initiative would have amended the Nebraska Constitution to allow the enactment of laws that authorize and tax gambling conducted by licensed gaming operators and held at licensed racetrack enclosures. Secretary Evnen argued that the language of the constitutional amendment would mislead voters. He said, The Constitutional Initiative effectively puts forth dual proposals: (1) authorizing expanded gambling at tribal casinos and (2) authorizing expanded gambling at racetracks by authorized operators. But the first proposal is hidden from the voters and impossible to ascertain from the text of the proposal. Putting forth dual propositions in a single proposal violates the single-subject rule as it does not permit voters to express a clear preference on dual propositions.

Authorizing Gaming at Racetracks Initiative: The initiative would have allowed games of chance by authorized operators in licensed racetrack enclosures; established a Nebraska Gaming Commission to regulate games of chance; and exempted gaming at racetracks from rules and penalties that govern other forms of gambling. The objectors argued that the provisions of the initiative violated the single-subject rule, which requires ballot initiatives to address a single issue or subject, because the initiative concerned regulation and taxation. Secretary Evnen disagreed with the objectors reasoning but determined that the initiative violated the single-subject rule because the inclusion of tax breaks for licensees [does] not have a natural and necessary connection to the primary purpose of regulating gambling.

Tax on Gaming at Racetracks Initiative: This initiative would have enacted a 20% tax on gambling revenue from games of chance operated at licensed racetracks and allocated 75% of the revenue from the tax to state funds for property tax relief and the Compulsive Gamblers Assistance Fund and 25% to the county or local jurisdictions in which the racetracks are located. Secretary Evnen argued that The property tax relief provisions contained in the Tax Initiative constitute logrolling and violate the single-subject rule.

As of August 26, 2020, three statewide ballot measures were certified for the general election ballot in Nebraska. One is a citizen-initiated measure that would cap the interest rate on payday loans. Two are constitutional amendments referred to the ballot by the state legislature.

The full text of Secretary Evnens letter can be found here: https://sos.nebraska.gov/sites/sos.nebraska.gov/files/doc/news-releases/Games%20of%20Chance%20Ballot%20Initiatives%20Determination%20Letter%202020.pdf

Additional reading:

Visit link:

Three initiatives that would authorize and tax gambling at racetracks in Nebraska will not make the November ballot - Ballotpedia News

How Bitcoin Gambling is Being Accepted Into Mainstream – Cryptonews

Posted on by

The text below is an advertorial article that was not written by Cryptonews.com journalists.

The use of bitcoin has become more and more frequent recently. The use of the most popular cryptocurrency is increasing, especially in the online casino industry, lotteries and sportsbooks. Even though some find it as a confusing and scary option, there is no reason why you shouldnt try.

There have been some problems with the industry of online betting since the beginning of the use of the internet. When it comes to casinos, just a few of them use only the bitcoin, while others use bitcoin as the addition to traditional currencies. Characteristics of the Bitcoin casinos that have turned the industry upside down, provide a lot of benefits for consumers. The product that can be a lot cheaper than the fiat-based systems offers an edge of 1% to 2%, while fiat-based casinos often charge 5% or even more for their games.

What helps bitcoin casinos to work is the software. Therefore, many casinos invest in developing their software, while others, usually less powerful casino companies use the rental version and adopt it by adding some features. To build trust, many bitcoin casinos openly discuss how the software work. The most popular game in bitcoin casinos is Poker. However, there are other interesting games as well. New ones are always being invented too.

While it seems that in many industries paying with bitcoin is quite complicated and usually not legally allowed, using bitcoin in betting is a completely different story. Because of the differences between the use of bitcoin in gambling and other industries, bitcoin casinos blossomed.

Apart from benefits regarding edges that are already mentioned, when gambling on bitcoin casinos, there is a real proof of solvency. Fiat-based casinos can promise an impressive jackpot but do they have resources to pay it out. Another benefit is related to Provably Fair gaming technology. It helps gamblers relax. They can be sure that, after placing the bet, the game will be fair. However, keep in mind that not every bitcoin casino has this kind of security.

Besides, its the online nature of the game that contributes to its popularity. Players from all over the world can easily play whenever they want. Some variations are not allowed with traditional currencies but happen to be common with bitcoin. So these variations must be one of the reasons for the popularity of bitcoin casinos.

Payments in traditional currencies help to identify players and casinos. However, when using bitcoin, individuals stay anonymous, which questions the fair business practices. While casinos that operate with traditional currencies require a lot of information, bitcoin casinos dont even ask for an age when verifying users.

Regulating bitcoin casinos is very complicated on a global level, so legal problems can be expected in some legislation.

People feel comfortable with doing something with a long tradition. That makes them feel safe. However, many say that after trying gambling in bitcoin casinos, because of many benefits that kind of gambling provides, gamblers wouldnt go back to traditional paying methods. Because of some ethical reasons that are always related to controversial cryptocurrencies, future challenges can be expected.

Link:

How Bitcoin Gambling is Being Accepted Into Mainstream - Cryptonews

Online Gambling and Betting Market to Witness Robust Expansion Throughout the Forecast Period 2024 : NetEnt AB, GVC Holdings Plc, 888 Holdings Plc -…

Posted on by

Get comprehensive research providing detailed regional analysis and growth outlook of the GlobalOnline Gambling and Betting Marketin the latest research report added by Big Market Research.

The report is an exhaustive analysis of this market across the world. It offers an overview of the market including its definition, applications, key drivers, key market players, key segments, and manufacturing technology. In addition, the study presents statistical data on the status of the market and hence is a valuable source of guidance for companies and individuals interested in the industry. Additionally, detailed insights on the company profile, product specifications, capacity, production value, and market shares for key vendors are presented in the report.

Request a sample of this premium research @:https://www.bigmarketresearch.com/request-sample/3773633?utm_source=SHASHI&utm_medium=ST

By Key Players:NetEnt AB, GVC Holdings Plc, 888 Holdings Plc, Ladbrokes Coral Group Plc, Fortuna Entertainment Group, Playtech Plc, William Hill Plc, Kindred Plc, Amaya Inc, Paddy Power Betfair Plc

A proper understanding of the Online Gambling and Betting Market dynamics and their inter-relations helps in gauging the performance of the industry. The growth and revenue patterns can be revised and new strategic decisions taken by companies to avoid obstacles and roadblocks. It could also help in changing the patterns using which the market will generate revenues. The analysis includes an assessment of the production chain, supply chain, end user preferences, associated industries, proper availability of resources, and other indexes to help boost revenues.

Regions & Top Countries Data Covered in this Report are:Asia-Pacific (China, Southeast Asia, India, Japan, Korea, Western Asia), Europe (Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland), North America (United States, Canada, Mexico), Middle East & Africa (GCC, North Africa, South Africa) , South America (Brazil, Argentina, Columbia, Chile, Peru).

The Online Gambling and Betting Market is gaining pace and businesses have started understanding the benefits of analytics in the present day highly dynamic business environment. The market has witnessed several important developments over the past few years, with mounting volumes of business data and the shift from traditional data analysis platforms to self-service business analytics being some of the most prominent ones.

With the help of in-depth research offered in the report, readers can effortlessly get detailed analysis of the key dynamics of the Online Gambling and Bettingmarket. The report also offers competitive landscape by providing detailed information on trends in competition, prominent players, and nature of competition. Additionally, it offers detailed analysis of the key segments of the market that helps in understanding the global trends in the Online Gambling and Betting Market. An overview of each market segment such as type, application, and region are presented in the report. Additionally, the report presents drivers, limitations, and opportunities for the Online Gambling and Bettingindustry, followed by industry news and policies.

Online Gambling and Betting Market By Type:

PokerCasinoSports BettingOther

Online Gambling and BettingMarket By Application:

EntertainmentCommercialOther

Reasons for Buying This Report:

The report provides insights on the following pointers:

North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Online Gambling and Betting industry.

Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Online Gambling and Betting industry.

Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, Netherlands, Switzerland, Belgium, China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Vietnam, Turkey, Saudi Arabia, United Arab Emirates, South Africa, Israel, Egypt, Nigeria, Brazil, Mexico, Argentina, Colombia, Chile, Peru) market size (sales, revenue and growth rate) of Online Gambling and Betting industry.

Different types and applications of Online Gambling and Betting industry, market share of each type and application by revenue.

Global market size (sales, revenue) forecast by regions and countries from 2020 to 2026 of Online Gambling and Betting industry.

Upstream raw materials and manufacturing equipment, downstream major consumers, industry chain analysis of Online Gambling and Betting industry.

Key drivers influencing market growth, opportunities, the challenges and the risks analysis of Online Gambling and Betting industry.

New Project Investment Feasibility Analysis of Online Gambling and Betting industry.

Request a discount on standard prices of this premium research @:https://www.bigmarketresearch.com/request-for-discount/3773633?utm_source=SHASHI&utm_medium=ST

Our analysis involves the study of the market taking into consideration the impact of the COVID-19 pandemic. Please get in touch with us to get your hands on an exhaustive coverage of the impact of the current situation on the market. Our expert team of analysts will provide as per report customized to your requirement.

Table of Content:

Industry Overview of Online Gambling and Betting

Major Manufacturers Analysis of Online Gambling and Betting

Global Price, Sales and Revenue Analysis of Online Gambling and Betting by Regions, Manufacturers, Types and Applications

North America Sales and Revenue Analysis of Online Gambling and Betting by Countries

Europe Sales and Revenue Analysis of Online Gambling and Betting by Countries

Asia Pacific Sales and Revenue Analysis of Online Gambling and Betting by Countries

Latin America Sales and Revenue Analysis of Online Gambling and Betting by Countries

Middle East & Africa Sales and Revenue Analysis of Online Gambling and Betting by Countries

Global Market Forecast of Online Gambling and Betting by Regions, Countries, Manufacturers, Types and Applications

Industry Chain Analysis of Online Gambling and Betting

New Project Investment Feasibility Analysis of Online Gambling and Betting

Conclusion of the Global Online Gambling and Betting Industry Market Professional Survey 2020

Appendix

About Us:

Big Market Research has a range of research reports from various publishers across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.We are instrumental in providing quantitative and qualitative insights on your area of interest by bringing reports from various publishers at one place to save your time and money. A lot of organizations across the world are gaining profits and great benefits from information gained through reports sourced by us.

Contact us:Mr. Abhishek Paliwal5933 NE Win Sivers Drive, #205, Portland,OR 97220 United StatesDirect: +1-971-202-1575Toll Free: +1-800-910-6452E-mail:[emailprotected]

Read more here:

Online Gambling and Betting Market to Witness Robust Expansion Throughout the Forecast Period 2024 : NetEnt AB, GVC Holdings Plc, 888 Holdings Plc -...

Guide to the Best Cryptocurrencies Used in Online Gambling – Cryptonews

Posted on by

Disclaimer: The text below is a press release that was not written by Cryptonews.com.

When cryptocurrencies first appeared, people were skeptical as they were unfamiliar with the way they worked. But, not too long after, crypto took the world by storm and made its way into almost every industry, especially online gambling, where players are always searching for safe ways to make payments to their accounts.

Thanks to their functionality, ease of use, top-notch secure technology, more and more gamblers are choosing cryptocurrencies over fiat money. Over time, a myriad of cryptocurrencies have appeared, but not all of them are worth trying out. Therefore, we have decided to choose the best cryptocurrencies you can use in online gambling without worrying about the safety of your info and money.

Bitcoin has been in the game since the beginning, and thats why its one of the most popular options when it comes to crypto payments. Even though the competition is heating up, and new cryptocurrencies are continually appearing, Bitcoin still manages to stay in the first place as the most common crypto payment option.

Initially released in 2018, EOS crypto is one of the newest additions to the cryptocurrency world, and it has quickly risen to the top of the ladder thanks to free transactions, speedy payments, and state-of-the-art security measures.

Safety has always been players top priority, but platforms that support EOS payments come with additional security, as EOS is thought to be among the safest crypto technologies available today. Since its a new payment option, you can read this intro to EOS crypto, to make yourself familiar with its benefits.

Similar to EOS, Ethereum is another blockchain-based crypto coin that uses smart contracts. That makes it impossible for third parties to get involved and makes every transaction perfectly safe. Thanks to the advanced technology, many players opt for this type of altcoin when they are making deposits and withdrawals in online gambling platforms.

Dogecoin stands out with its design because its symbol is a Shiba Inu dog. Even though no one was taking this crypto coin seriously in the beginning, it quickly became a full-fledged cryptocurrency platform with millions of users worldwide. Today, most online casinos that support digital coins include Dogecoin in their offer.

Usually referred to as the Bitcoin twin, Litecoin is an autonomous and decentralized currency that uses a more complex algorithm that allows it to process transactions faster than Bitcoin. Thanks to its speed, punters and casino players often choose Litecoin as their favorite payment option.

The blockchain technology is always changing, adding new features and improving its performance. The online gambling industry and its users benefit from the use of cryptocurrencies, and heres why:

Read the original here:

Guide to the Best Cryptocurrencies Used in Online Gambling - Cryptonews

‘Safer gambling must no longer be allowed to exist in a compliance-oriented silo’ – Yogonet International

Posted on by

A

head of his appearance at Septembers SBC Summit Barcelona - Digital, Rank Groups Director of Public Affairs David Williams spoke to Yogonet about the Grosvenor Casinos, Mecca and Enracha operators approach to player safety and how the industry can respond to political pressure on the issue of safer gambling.

What are the main safer / problem gambling issues faced by Rank? And do they differ much between land-based and online, and between casino and bingo?

The overarching requirement for any operator to make a meaningful improvement in safer gambling progress is to deliver a positive shift in colleague behaviour. This is most obvious in our venues with front-line staff in the vanguard of giving our customers a safe and enjoyable experience, but the cultural imperative to ensure every colleague in the business subscribes to the need for excellence in this space is huge, irrespective of platform. How we train our colleagues and how we manage customer interactions - on our digital platforms and in our venues - is critical to securing the right level of protection without introducing clunky and needless friction for the customer.

Did the UK Gambling Commissions additional guidance on customer interaction during lockdown have much impact on the business? And is any of it worth continuing with?

The UKGCs additional guidance must also be seen alongside the Ten Pledges provided and implemented by Betting & Gaming Council members, including Rank, who were keen to get on the front foot and demonstrate an elevated commitment to safer gambling as the unforeseen impacts of lockdown played out. Securing the correct balance between responding to the elevated challenges possibly faced by some customers during a pandemic whilst also ensuring operators are able to continue on their own roadmap of progress without being derailed by poorly-conceived mandates will always be important. Safer gambling is always evolving and, as operators, we welcome all measures that better protect those customers who need protection. By the same token, we need to resist and remove any unnecessary, untargeted friction that does little to benefit customers and serves only to increase the burden on operators and frustrate the vast majority of customers whose enjoyment of gambling may be compromised by clumsy barriers or interventions.

Problem gambling has caught the attention of politicians in the last few years and the likes of the Gambling Related Harm APPG and the Social Market Foundation have made a wide range of proposals (including stake limits for online slots, a total ban on gambling advertising and VIP schemes, a monthly deposit limit, and a single sign-on mechanism for all online operators). Do any of the recent suggestions really tackle the problem? And are there any you would like to see become law?

We welcome all constructive input to the ongoing discussion which seeks to offer better protection to those customers who experience gambling-related harm whilst ensuring operators are able to safely grow their well-regulated businesses with safer gambling at its core. Frustratingly, in some but not all cases, a desire to secure headlines at the expense of evidential analysis has led to a distortion of the discussion which, in real terms, will not protect those who need the most protection. Some of the most eye-catching proposals are unlikely to be a panacea in the way in which they have been presented, and will ultimately trigger sequences of events which could take those experiencing (or at risk of) gambling-related harm further away from the help they would get within the regulated system. Some recommendations - including the role of an Ombudsman, and securing appropriate levels of funding to support targeted RET services - are clearly sensible.

What can the betting and gaming industry do now to improve player safety, and in doing so, get ahead of calls for much tighter regulation?

The progress that the industry has made in the past year or two - irrespective of whether or not the progress has translated into public or media perception - has been significant. Tightening of regulation, where targeted and founded in evidence-based analysis, is not something the industry ought to resist. Beyond that, however, safer gambling must no longer be allowed to exist in a compliance-oriented silo. Operators must demonstrate a far more ambitious vision to embed safer gambling into the culture of our businesses by demonstrating faultless behaviour at every customer touchpoint. Rewarding excellence amongst colleagues and empowering customers to feel safe when they are engaging with us will rightly improve our chances of ensuring we are not subjected to misguided and poorly targeted regulatory creep.

Could technology have a greater role to play than regulation in improving player safety?

Data is indisputably king. Both in venues and across our digital platforms, the more high-quality data we can rely on to inform our safer gambling practices, interventions and systems, the better. However, it is only part of the story, and without the cultural desire from every single colleague to play their part in using data appropriately to provide a richer, safer customer experience, well only get half way down the road. Blending the very best technological tools with the right mindset from colleagues who can use the technology will bring about more compelling improvements to the safer gambling piece than we might have imagined.

David Williams will be speaking in the Payments & Compliance Zone at SBC Summit Barcelona - Digital, the virtual edition of the global betting and gaming show. The event takes place on 8 - 11 September, and full details of the agenda, line-up of 200 expert speakers and the interactive exhibition are available from the official website. To join the 10,000 delegates from around the world, click here to register for free.

Continue reading here:

'Safer gambling must no longer be allowed to exist in a compliance-oriented silo' - Yogonet International

Gambling recovered from Covid, but could now be laid low by legal hurdles – The Guardian

Posted on by

The house always wins, even in the midst of a pandemic. In the early days of lockdown, as the stock market lurched into stomach-churning freefall, the share prices of Britains gambling powerhouses also tanked.

The cancellation of sports events cut off the steady revenue stream that many had come to enjoy, not just from horse racing but, increasingly, from football betting, which typically involves small stakes but extremely high volumes.

With no certainty over the return of sport and of the football cash cow in particular the immediate future looked bleak. Since then, two things have happened.

First, football has returned behind closed doors and the fixture calendar boffins are making up for lost time by scheduling games more or less every day, with more of them televised than ever before.

Second, firms with a strong offering in areas such as online poker and casino games have enjoyed a significant uptick in website traffic, as the boredom of lockdown helped spur new account sign-ups.

On Thursday, the worlds largest online gambling firm, Flutter Entertainment, will update the market on its performance in the six months to the end of June.

Flutter the owner of Paddy Power Betfair has been one of the most resilient performers in the sector, thanks to its scale and diversification in both geography and the products it can boast since its $6bn mega-merger with Canadas The Stars Group, which includes Sky Betting and Gaming.

While some UK rivals such as William Hill still rely all too heavily on UK sports betting customers, Flutter has an array of impressive arrows in its quiver.

The deal with Stars saw it acquire PokerStars, one of the leading global brands, as well as a sizable presence in Australia and an improved casino range. This, according to Russ Mould, investment director at stockbroker AJ Bell, made Flutter one of the firms best-suited to helping or entertaining the UKs population while it was under lockdown.

Flutter also owns FanDuel, a fantasy sports betting site used by more than 8 million sports fans in the rapidly expanding, newly liberalised US market in which Flutter like every British gambling company is trying to establish a beachhead.

Covid-19 will probably result in a faster rate of US sports betting legalisation, potentially followed by online casino legalisation, in our view, say analysts at Jefferies.

All of this helps explain why Flutter Entertainment is valued at more than 40% more now than it was at the start of March, while rivals GVC (owner of Ladbrokes Coral) and William Hill have struggled to make up the ground they lost during lockdown.

Industry insiders say management at Flutter have also put in a more impressive performance than their rivals, particularly after GVCs veteran boss, Kenny Alexander, announced his intention to step down.

Any signs in Thursdays numbers of a stronger-than-expected recovery in sports betting could provide a further shot in the arm, not just for Flutter but for some of its more sport-focused peers, too.

And yet not all is rosy in the gambling garden, and 2020 could prove to be one of the most important years in the history of the UK industry, a sector which is genuinely world-leading.

So far, firms including Flutter and casino-focused rivals such as 888 have navigated the choppy waters of the pandemic adroitly.

But this year will also see the government kick off its review of the 2005 Gambling Act, the legislation introduced by Tony Blairs government that gave Britain one of the most liberal gambling markets in the world, and created the industry we see today. There is a broad cross-party consensus that the regulatory pendulum must now swing back in the other direction.

If that happens, as with the pandemic, Flutters size and diversification will serve it well.

But it will also make the stakes for its US expansion much higher, and with no shortage of competition for American punters, that is going to be a fierce battle.

Flutter and the broader industry have ridden out the coronavirus pretty well but the real dangers still lie ahead.

Originally posted here:

Gambling recovered from Covid, but could now be laid low by legal hurdles - The Guardian

As online gambling expands in the U.S., experts worry Nevada could be left behind – Northern Nevada Business Weekly

Posted on by

In April and May combined, when Nevadas casinos were closed to slow the spread of COVID-19, statewide gaming revenues totaled $9.44 million, a more than 99 percent decline over the same two months in 2019.

Gaming win came from mobile sports wagering on Belarusian soccer, Korean baseball, Chinese table tennis, other non-traditional games and gambling on WSOP.com Nevadas lone online poker site.

It was a different story in New Jersey and Pennsylvania.

Both states casinos were also closed, but New Jersey gaming revenues totaled $178.4 million over the two months. Pennsylvania reported $108 million.

The difference was online gaming, which accounted for more than 75 percent of the revenue.

The websites in those states are not just dedicated to poker but also include wagering on table games and slot machines with the same themes found in traditional casino settings.

New Jersey and Pennsylvania have multiple online gaming websites affiliated with gaming companies tied to Nevada, including MGM Resorts International, Golden Nugget and Caesars Entertainment, which owns the World Series of Poker-affiliated WSOP site.

From our organizations perspective, Nevada is missing out, said John Pappas, spokesman for the Washington D.C.-based iDevelopment and Economic Association, which goes by iDEA Growth, a trade organization for the digital and interactive gaming community.

We recognize that change in Nevada has to be spearheaded by the brick and mortar casinos, Pappas said. There can be a tremendous amount of benefit.

Eilers and Krejcik Gaming Research analyst Chris Grove said a healthy debate could take place in comparisons of New Jerseys growing online gaming market with Nevadas online casino potential.

Its evident to us that the introduction of online casino would have an additive impact on the total amount of gambling revenue generated by the Nevada locals market, Grove said.

A Caesars representative said the company wasnt aware of momentum in Nevada for legalizing online casino games. A spokeswoman for BetMGM MGMs joint venture online wagering application said it would offer online gaming once its allowed in Nevada.

Texas casino and restaurant developer Tilman Fertitta is spinning off Golden Nuggets online gaming business into a public company this year, looking to grow outside its market-leading presence in New Jersey. Nevada, where Fertitta owns the Golden Nugget casinos in downtown and Laughlin, could be a target.

We look forward to expanding our operations to Pennsylvania and Michigan, where our licensing process is ongoing, Golden Nugget Online Gaming General Manager Thomas Winter said in a statement. We are closely monitoring the legislative momentum in other states.

Nevada lawmakers legalized internet gaming for a brief time in 2002. The efforts were halted when the Department of Justice advised the state that federal law prohibited internet gambling.

After the Federal Wire Act was reinterpreted by the U.S. Department of Justice in December 2011, a handful of states explored online gaming legalization. Nevada lawmakers approved online poker in 2013.

Today, five states offer online gaming Delaware, Pennsylvania, Nevada (poker only), New Jersey and West Virginia. Michigan has legalized online gaming but has not yet gone live with the activity. Seven states had online gaming legislation pending in the spring before the coronavirus outbreak caused lawmakers to suspend sessions indefinitely.

Earlier this month, the American Gaming Association said the impact COVID-19 had on second quarter gaming revenues nationwide amounted to a 79 percent decline compared to a year ago. All gaming verticals but one online gaming showed double-digit decreases.

Combined, the five online gaming states produced revenues of $402.7 million for the quarter, an increase of almost 254 percent.

AGA CEO Bill Miller noted the quarter was the first time that online gaming recorded higher revenues than sports betting, which was legalized in May 2018.

What about Nevada?

So why hasnt Nevada legalized online casinos?

The simple answer is lack of consensus in the casino industry.

Las Vegas Sands Corp. has not moved from its nearly decade-long opposition to online gaming. Company Chairman and CEO Sheldon Adelson once vowed to spend millions to kill the activity.

On the other end of spectrum, billionaire media mogul Barry Diller spent more than $1 billion through IAC/Interactive Corp. this summer to acquire a 12 percent ownership stake in MGM Resorts. His primary focus is MGMs interactive gaming business.

Diller, who is chairman and senior executive of IAC, said online gaming currently comprises a tiny portion of its revenue. Its so small, he said, that it rounds down to zero.

In 2018, MGM Resorts and United Kingdom-based sports betting conglomerate GVC Holdings partnered to form Roar Digital, which oversees the BetMGM app. The product is live in seven states and expects to be operating in 11 states by the end of 2020.

There is a digital-first opportunity within MGM Resorts already impressive offline businesses, and with our experience, we hope we can strongly contribute to the growth of online gaming, said Diller, who founded Fox Broadcasting and USA Broadcasting.

Other Nevada-based casino operators have launched online gaming outside of the Silver State. Caesars has online gaming sites in New Jersey and Pennsylvania while Boyd Gaming is a partner with FanDuel in an online casino in Pennsylvania that is tied to Boyds Valley Forge Casino.

Grove said Nevadas unique gaming market is unlike the rest of the country in its saturation of casinos geared to different customer demographics.

Nevada has a far greater variety of retail gambling outlets, a smaller population, and a greater density of total population proximate to the full range of retail gambling outlets than youll find in any other state, Grove said. All of that makes precise forecasting of Nevadas online casino potential a challenging task.

Adding online casinos in Nevada

If state gaming regulators with casino industry backing decide to add online casinos, there isnt a need to go back to the Legislature.

Longtime gaming attorney Tony Cabot, now a Distinguished Fellow in Gaming Law at UNLVs Boyd School of Law, said the framework is clearly in place following the passage of previous efforts.

The gaming commission was uncomfortable doing anything beyond poker, Cabot said. The regulations governing internet casinos would just have to be approved.

Gaming Control Board Chairwoman Sandra Douglass Morgan said the Gaming Policy Committee, under then-Gov.Brian Sandoval, met in 2016 and discussed online gaming and future opportunities for Nevada.

However, there was no decision to expand interactive gaming beyond internet poker at that time, Morgan said. Still, state gaming law allows interested parties to petition the Nevada Gaming Commission for regulation changes.

If a policy decision is made to expand interactive gaming beyond internet poker, the Gaming Control Board will fulfill its statutory duty to ensure interactive gaming is properly regulated, Morgan said.

Cabot, who has written extensively on internet gaming, questioned whether Nevadas market size could support the investment casinos would need to make to launch full-scale online gaming. He believes one casualty would be the growing social gaming business, where customers play free casino games and slots online in exchange for virtual tokens.

Pappas said internet gaming would only enhance a casinos offerings.

Nevada has done a great job embracing mobile sports betting, Pappas said. The state needs to take it one step further.

Online poker history

After launching in 2013, Nevada at its height had three poker websites: WSOP.com, South Points Real Gaming and Station Casinos Ultimate Poker, which was the first to launch in April 2013, but was closed after 19 months.

By statute, state gaming regulators only release gaming revenue figures when there are three reporting businesses. Just once in the eight months that Nevada had three poker sites did online gaming combine to produce more than $1 million in revenue $1.037 million in June 2014.

In 2015, Nevada signed a multistate poker network agreement with Delaware where players from the two states could share poker tables and tournaments. The network still exists, and New Jersey joined a few years later.

Growing business

Internet gaming has not expanded at the same pace as sports betting, which is now available in 18 states with another four states potentially able to launch before the end of 2020. In 2019, gamblers nationwide legally wagered more than $13 billion on sports, a figure that was easily on track to be crushed in 2020 until COVID-19 shut down college and professional sports and the gaming industry.

While the interest for digital gaming has picked up, Nevada could be left behind.

Boston-based DraftKings went public in April and since June, the company has launched sports betting in Colorado, an online casino in Pennsylvania, sports betting in Illinois and an online casino in West Virginia. DraftKings is working to enter the Virginia and Tennessee markets for sports betting and Michigan for sports betting and online gaming.

DraftKings does not have any operations in Nevada.

Penn National Gaming, which operates Tropicana Las Vegas, M Resort and two casinos in the northeastern Nevada town of Jackpot, is preparing to roll out a sports betting and online game app in partnership with sports media platform Barstool Sports.

Penn spent $163 million to acquire 36 percent of Barstool in February, looking to attract the platforms 66 million-member fan base.

Penn CEO Jay Snowden recently told private investors at a meeting hosted by Truist Securities that the Barstool branded app would launch in Pennsylvania in September and in Michigan by November. New Jersey, Indiana, Iowa, West Virginia and Colorado would roll out in early 2021, he said.

Nevada was not mentioned, and no reason was given.

Some analysts suspect the IAC investment into MGM Resorts could jumpstart online gaming in many states, including Nevada.

IAC is clearly taking a long-term view of the online opportunity within gaming, said Deutsche Bank gaming analyst Carlo Santarelli.

James Wheatcroft, a United Kingdom-based gaming analyst for Jefferies, expressed a bright future for the U.S. online gambling market, projecting $19 billion in revenue from sports betting by 2023.

We anticipate that (internet) gaming is the next logical step in the legislative process, with casino-oriented MGM well placed to benefit, he said.

Disclosure: Chris Grove, mentioned in this story, has donated $2,550 toThe Nevada Independentthrough 404 LLC.

Howard Stutz is a freelance gaming reporter for The Nevada Independent and the executive editor of CDC Gaming Reports. He has been a Nevada journalist for 30 years. He can be reached athowardmstutz@gmail.com. On Twitter: @howardstutz.

The Nevada Independent is a 501(c)3 nonprofit news organization. The following people or entities mentioned in this article are financial supporters: Anthony Cabot$505.00; Boyd Gaming$31,500.00; Brian Sandoval$550.00; Caesars Entertainment$155,200.00; MGM Resorts International$957,500.00; Sandra Douglass Morgan$100.00; and Station Casinos$100,000.00.

Read the original:

As online gambling expands in the U.S., experts worry Nevada could be left behind - Northern Nevada Business Weekly